The approval was expedited through the FDAs National Priority Voucher program, a new initiative designed to speed up access to treatments addressing major public health needs
December 2025: On December 15, 2025, the Judicial Panel on Multidistrict Litigation entered an order approving the creation of an MDL to house federal vision loss claims for Wegovy and other GLP-1 drugs
Patients with MTHFR gene variants experience GI side effects more intensely and benefit from methylated B vitamin co-supplementation during the adaptation phase
These formulations, meticulously designed to amplify therapeutic efficacy, represent the cornerstone of TCMs holistic approach
Industry analysts suggest that the introduction of FDA-approved oral GLP-1 medications may shift competitive dynamics within the weight loss treatment market
doi: 10.1111/ejn.15676 [DOI] [PubMed] [Google Scholar] 157.Pradhan N, Singh C, Singh A